VKTX250110P56000
- 14.27
- 0.000.00%
Viking Therapeutics Newsroom
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $105
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
Positive Outlook for Viking Therapeutics Amid Promising Trial Developments
Viking Therapeutics' Oral-2735 Could Differentiate Asset, Says JPMorgan
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics Analyst Ratings
Express News | Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients With Obesity
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Insider Sale: President & CEO of $VKTX (VKTX) Sells 175,490 Shares
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
Express News | Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 8.31 Million in Common Stocks
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?